Canigen L4

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Inaktivirano sojeva лептоспир: l. interrogans серогруппы Кашницкого серовара Portland-vjeri (soj Sa-12-000); l. interrogans серовара Copenhageni серогруппы Icterohaemorrhagiae (soj SC-02-001); l. interrogans серогруппы Аустралис серовара Bratislava (soj Ac-05-073); l. kirschneri серогруппы Grippotyphosa серовара Dadas (soj gr-01-005)

Available from:

Intervet International B.V.

ATC code:

QI07AB01

INN (International Name):

Canine leptospirosis vaccine (inactivated)

Therapeutic group:

psi

Therapeutic area:

Imunomodulatori za псовые, inaktivirano bakterijskih cjepiva (uključujući i микоплазмы, анатоксин i klamidija)

Therapeutic indications:

Za aktivnu imunizaciju pasa protiv: L. interrogans серогруппы Кашницкого Кашницкого серовара za smanjenje infekcije i izlučivanje;l. interrogans серогруппы Icterohaemorrhagiae Copenhageni серовара za smanjenje infekcije i izlučivanje;l. interrogans серогруппы Аустралис серовара Bratislava za smanjenje infekcije;l. kirschneri серогруппы Grippotyphosa Бананал серовара/Lianguang za smanjenje infekcije i izlučivanje.

Product summary:

Revision: 6

Authorization status:

odobren

Authorization date:

2015-07-03

Patient Information leaflet

                                13
B.
UPUTA O VMP
14
UPUTA O VMP
CANIGEN L4, SUSPENZIJA ZA INJEKCIJU ZA PSE
1.
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
PROIZVODNE SERIJE, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet i proizvođač odgovoran za
puštanje serije u promet:
Intervet International B.V.
Wim de Körverstraat 35
NL-5831 AN Boxmeer
Nizozemska
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Canigen L4 suspenzija za injekciju za pse
3.
NAVOĐENJE DJELATNE(IH) TVARI I DRUGIH SASTOJAKA
Svaka doza od 1 ml sadrži:
DJELATNE TVARI:
Inaktivirani sojevi
_ Leptospira_
:
-
_L. interrogans, _
serogrupa Canicola, serovar Portland-vere (soj Ca-12-000)
3550 - 7100 U
1
-
_L. interrogans, _
serogrupa Icterohaemorrhagiae, serovar Copenhageni
(soj Ic-02-001)
290 - 1000 U
1
-
_L. interrogans, _
serogrupa Australis, serovar Bratislava (soj As-05-073)
500 - 1700 U
1
-
_L. kirschneri, _
serogrupa Grippotyphosa, serovar Dadas (soj Gr-01-005)
650 - 1300 U
1
1
Antigena masa ELISA jedinice.
Bezbojna suspenzija.
4.
INDIKACIJE
Za aktivnu imunizaciju pasa protiv:
-
_L. interrogans, _
serogrupa Canicola, serovar Canicola za smanjenje infekcije i
izlučivanja putem
urina,
-
_L. interrogans, _
serogoupa Icterohaemorrhagiae, serovar Copenhagen za smanjenje
infekcije i
izlučivanja putem urina,
-
_L. interrogans, _
serogrupa Australis, serovar Bratislava za smanjenje infekcije,
-
_L. kirschneri, _
serogrupa Grippotyphosa, serovar Bananal/Lianguang za smanjenje
infekcije i
izlučivanja putem urina.
Početak imunosti: 3 tjedna.
Trajanje imunosti: 1 godina.
5.
KONTRAINDIKACIJE
Nema.
15
6.
NUSPOJAVE
Prolazno, blago povećanje tjelesne temperature (
≤
1
°
C) vrlo često se pojavljuje nekoliko dana nakon
cijepljenja uz smanjenu aktivnost i/ili smanjen apetit kod nekih
štenaca. Prolazna oteklina na mjestu
prrimjene (
≤
4 cm), koja se često pojavljivala u kliničkim ispitivanjima, ponekad
može biti tvrda i
bolna na dodir. Oteklina će se znatno smanjiti ili će nestati do 14
dana pos
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Canigen L4 suspenzija za injekciju za pse
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Svaka doza od 1 ml sadrži:
DJELATNA TVAR:
Inaktivirani sojevi
_Leptospira _
:
-
_L. interrogans, _
serogrupa Canicola, serovar Portland-vere
3550 - 7100 U
1
(soj Ca-12-000)
-
_ L. interrogans,_
serogrupa Icterohaemorrhagiae, serovar Copenhageni 290 - 1000 U
1
(soj Ic-02-001)
-
_L. interrogans, _
serogrupa Australis, serovar Bratislava
500 - 1700 U
1
(soj As-05-073)
-
_ L. kirschneri,_
serogrupa Grippotyphosa, serovar Dadas
650 - 1300 U
1
(soj Gr-01-005)
1
Antigena masa ELISA jedinice.
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
3.
FARMACEUTSKI OBLIK
Suspenzija za injekciju.
Bezbojna suspenzija.
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Psi.
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Za aktivnu imunizaciju pasa protiv:
-
_L. interrogans, _
serogrupa Canicola, serovar Canicola, za smanjenje infekcije i
izlučivanja putem
urina,
-
_L. interrogans, _
serogoupa Icterohaemorrhagiae, serovar Copenhagen, za smanjenje
infekcije i
izlučivanja putem urina,
-
_L. interrogans, _
serogrupa Australis, serovar Bratislava, za smanjenje infekcije,
-
_L. kirschneri, _
serogrupa Grippotyphosa, serovar Bananal/Lianguang, za smanjenje
infekcije i
izlučivanja putem urina.
Početak imunosti: 3 tjedna.
Trajanje imunosti: 1 godina.
4.3
KONTRAINDIKACIJE
Nema.
4.4
POSEBNA UPOZORENJA ZA SVAKU OD CILJNIH VRSTA ŽIVOTINJA
3
Cijepiti samo zdrave životinje.
4.5
POSEBNE MJERE PREDOSTROŽNOST ZA PRIMJENU
Posebne mjere opreza prilikom primjene na životinjama
Nije primjenjivo.
Posebne mjere opreza koje mora poduzeti osoba koja primjenjuje
veterinarsko-medicinski proizvod na
životinjama
Izbjegavati slučajno samoinjiciranje ili kontakt s očima. U slučaju
kontakta s očima, isperite oko(či) s
vodom. U slučaju samoinjiciranja ili iritacije očiju odmah
potražite liječničku pomoć i pokažite mu
uputu o VMP ili etiketu.
4.6
NUSPOJAVE (UČESTALOS
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 08-07-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 08-07-2021
Public Assessment Report Public Assessment Report Bulgarian 30-07-2015
Patient Information leaflet Patient Information leaflet Spanish 08-07-2021
Public Assessment Report Public Assessment Report Spanish 30-07-2015
Patient Information leaflet Patient Information leaflet Czech 08-07-2021
Public Assessment Report Public Assessment Report Czech 30-07-2015
Patient Information leaflet Patient Information leaflet Danish 08-07-2021
Public Assessment Report Public Assessment Report Danish 30-07-2015
Patient Information leaflet Patient Information leaflet German 08-07-2021
Public Assessment Report Public Assessment Report German 30-07-2015
Patient Information leaflet Patient Information leaflet Estonian 08-07-2021
Public Assessment Report Public Assessment Report Estonian 30-07-2015
Patient Information leaflet Patient Information leaflet Greek 08-07-2021
Public Assessment Report Public Assessment Report Greek 30-07-2015
Patient Information leaflet Patient Information leaflet English 07-05-2020
Public Assessment Report Public Assessment Report English 30-07-2015
Patient Information leaflet Patient Information leaflet French 08-07-2021
Public Assessment Report Public Assessment Report French 30-07-2015
Patient Information leaflet Patient Information leaflet Italian 08-07-2021
Public Assessment Report Public Assessment Report Italian 30-07-2015
Patient Information leaflet Patient Information leaflet Latvian 08-07-2021
Public Assessment Report Public Assessment Report Latvian 30-07-2015
Patient Information leaflet Patient Information leaflet Lithuanian 08-07-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 08-07-2021
Public Assessment Report Public Assessment Report Lithuanian 30-07-2015
Patient Information leaflet Patient Information leaflet Hungarian 08-07-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 08-07-2021
Public Assessment Report Public Assessment Report Hungarian 30-07-2015
Patient Information leaflet Patient Information leaflet Maltese 08-07-2021
Public Assessment Report Public Assessment Report Maltese 30-07-2015
Patient Information leaflet Patient Information leaflet Dutch 08-07-2021
Public Assessment Report Public Assessment Report Dutch 30-07-2015
Patient Information leaflet Patient Information leaflet Polish 08-07-2021
Public Assessment Report Public Assessment Report Polish 30-07-2015
Patient Information leaflet Patient Information leaflet Portuguese 08-07-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 08-07-2021
Public Assessment Report Public Assessment Report Portuguese 30-07-2015
Patient Information leaflet Patient Information leaflet Romanian 08-07-2021
Public Assessment Report Public Assessment Report Romanian 30-07-2015
Patient Information leaflet Patient Information leaflet Slovak 08-07-2021
Public Assessment Report Public Assessment Report Slovak 30-07-2015
Patient Information leaflet Patient Information leaflet Slovenian 08-07-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 08-07-2021
Public Assessment Report Public Assessment Report Slovenian 30-07-2015
Patient Information leaflet Patient Information leaflet Finnish 08-07-2021
Public Assessment Report Public Assessment Report Finnish 30-07-2015
Patient Information leaflet Patient Information leaflet Swedish 08-07-2021
Public Assessment Report Public Assessment Report Swedish 30-07-2015
Patient Information leaflet Patient Information leaflet Norwegian 08-07-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 08-07-2021
Patient Information leaflet Patient Information leaflet Icelandic 08-07-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 08-07-2021

View documents history